Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mimetogen Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Mimetogen Pharmaceuticals Inc.'s founding goal was to use synthetic analogs of nerve growth factor to protect the retinal ganglion cells of the optic nerve that die as glaucoma progresses. In doing so, it intended to show that its drugs provided neuroprotective ability and also enhanced this effect for other treatments prescribed to lower intraocular pressure. Mimetogen validated that program in animals, but given the cost and length of clinical trials for glaucoma, the company switched gears and began developing its NGF mimetics as potential treatments for dry eye.

You may also be interested in...



Deals Of The Week: Tire-Kicking Season Continues Full-Swing

As Roche’s reported interest in buying rare-disease specialist Alexion faded, new suitors popped up for oncology specialist Onyx. Plus news on deals between Spectrum and Talon, Pfizer and Sequella, Medtronic and Amgen, and a new direction for Rexahn.

Start-Up Previews (10/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Eyeing New Drugs For Glaucoma," features profiles of Altheos, Amakem and Mimetogen Pharmaceuticals. Plus these Start-Ups Across Health Care: Aragon Surgical, Arcarios, Carolina BioPharm, Miromatrix Medical and Pathogenica.

Altheos Inc.

At its inception, Altheos licensed a series of selective Rho-kinase inhibitors for glaucoma from Asahi Kasei Pharma, and it plans to move the lead candidate into clinical trials in the coming year. Although the start-up is behind several companies that already have ongoing ROCK inhibitor trials, Altheos believes its approach to drug discovery and medicinal chemistry make its therapeutic likely to prove itself the best among the new class of medicines for staving off vision loss from glaucoma.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC092041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel